title: Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia.
abstract: Macroprolactinemia is hyperprolactinemia in humans mainly due to anti-PRL (prolactin) autoantibodies and is a pitfall for the differential diagnosis of hyperprolactinemia. Despite its high prevalence, the pathogenesis remains unclear. In this study, we examined whether anti-PRL autoantibodies develop via immunization with homologous rat pituitary PRL in rats to elucidate what mechanisms are involved and whether they cause hyperprolactinemia with low PRL bioactivity, as seen in human macroprolactinemia. Anti-PRL antibodies were developed in 19 of 20 rats immunized with homologous rat pituitary PRL and 29 of 30 rats with heterogeneous bovine or porcine pituitary PRL but did not develop in 25 control rats. In rats with anti-PRL antibodies, the basal serum PRL levels were elevated, and a provocative test for PRL secretion using dopamine D2 receptor antagonist (metoclopramide) showed a normal rising response with a slower clearance of PRL because of the accumulation of macroprolactin in blood. Antibodies developed by porcine or rat pituitary PRL reduced the bioactivity of rat serum PRL, and gonadal functions in these rats were normal despite hyperprolactinemia. Anti-PRL antibodies were stable and persisted for at least 5 wk after the final injection of PRL. These findings suggest that pituitary PRL, even if homologous, has antigenicity, leading to the development of anti-PRL autoantibodies. We successfully produced an animal model of human macroprolactinemia, with which we can explain the mechanisms of its clinical characteristics, i.e. asymptomatic hyperprolactinemia.
authors.affiliation: Department of Pharmacology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi-City, Osaka 570-8506, Japan. hattorin@takii.kmu.ac.jp
authors.forename: Naoki
authors.initials: N
authors.lastname: Hattori
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Kaori
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Tiesong
authors.initials: T
authors.lastname: Li
authors.forename: Chiyoko
authors.initials: C
authors.lastname: Inagaki
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000494:pharmacology; D000939:Epitopes; D030762:Estrous Cycle / Q000502:physiology; D005260:Female; D006966:Hyperprolactinemia / Q000188:drug therapy / Q000276:immunology*; D007114:Immunization; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D011388:Prolactin / Q000097:blood* / Q000276:immunology*; D051381:Rats; D013739:Testosterone / Q000097:blood
chemical_list: D001323:Autoantibodies; D018492:Dopamine Antagonists; D000939:Epitopes; D013739:Testosterone; D011388:Prolactin; D008787:Metoclopramide